



## **Singular Genomics to Present at the 41st Annual J.P. Morgan Healthcare Conference**

December 21, 2022

SAN DIEGO, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced plans to present at the 41<sup>st</sup> Annual J.P. Morgan Healthcare Conference in San Francisco, California.

Singular Genomics' management is scheduled to present on Thursday, January 12, 2023 at 10:30 a.m. Pacific Time / 1:30 p.m. Eastern Time.

Investors and other interested parties are invited to listen to a live and recorded webcast of the presentation on the News & Events section of the company's investor relations website at <https://investor.singulargenomics.com/news-events/event-calendar>.

### **About Singular Genomics Systems, Inc.**

Singular Genomics is a life science technology company that develops next-generation sequencing and multiomics technologies. The commercially available G4 Sequencing Platform is a powerful, highly versatile benchtop genomic sequencer designed to produce fast and accurate results. In development, the PX system leverages Singular's proprietary sequencing technology, applying it as an in-situ readout to look at RNA and proteins in single cells and tissue. With these products, Singular Genomics' mission is to empower researchers and clinicians to advance science and medicine.

### **Investor Contact**

Matt Clawson  
949-370-8500  
[ir@singulargenomics.com](mailto:ir@singulargenomics.com)

### **Media Contact**

Dan Budwick, 1AB  
973-271-6085  
[dan@1abmedia.com](mailto:dan@1abmedia.com)



Source: Singular Genomics Systems, Inc.